Oncogenetic landscape of lymphomagenesis in coeliac disease
Sascha Cording,Ludovic Lhermitte,Georgia Malamut,Sofia Berrabah,Amélie Trinquand,Nicolas Guegan,Patrick Villarese,Sophie Kaltenbach,Bertrand Meresse,Sherine Khater,Michael Dussiot,Marc Bras,Morgane Cheminant,Bruno Tesson,Christine Bole-Feysot,Julie Bruneau,Thierry Jo Molina,David Sibon,Elizabeth Macintyre,Olivier Hermine,Christophe Cellier,Vahid Asnafi,Nadine Cerf-Bensussan,CELAC network,Yoram Bouhnik,Charles-André Cuenod,Sabine Brechignac,Matthieu Allez,Jacques Cosnes,Agnès Fourmestraux,Jean-Charles Delchier,Jehan Dupuis,Corinne Haioun,Taoufik El Gnaoui,Eric Lerebours,Guillaume Savoye,Herve Tilly,Bernard Flourie,Bertrand Coiffier,Xavier Hebuterne,Nadia Arab,Jérôme Filippi,Stéphane Schneider,Frank Zerbib,Noel Milpied,Krimo Bouabdallah,Reza Tabrizi,Stéphane Vigouroux,Arnaud Pigneux,Thibaut Leguay,Marie-Sarah Dilhuydy,Charles Dauriac,Serge Bologna,Cyrille Hulin,Caroline Bonmati,Fréderic Magnin,Dana Ranta,Tamara Matysiakbudnik,Eric Deconinck,Philippe Pouderoux,Bruno Bonaz,Remy Gressin,Franck Carbonnel,Jean-Marc Gornet,Julien Branche,Georgette Saint-Georges,Jean-Marie Reimund,Stéphane Nancey,Maria Nachury,Stéphanie Viennot,Camille Zallot,Bettina Fabiani,Lysiane Marthey,Karine Juvin,Yann Le Baleur,Sandy Kwiatek,Eric Saillard,Dominique Louvel,Xavier Roblin,Philippe Beau,Pierre Feugier,Laurent Peyrin-Biroulet,Hélène Zanaldi,Hedia Brixi-Benmansour,Guillaume Cadiot,Thierry Lecomte,Jean-Francois Bretagne,Olivier Casasnovas,Denis Caillot,Laurent Bedenne,Jacques-Olivier Bay,Corinne Bouteloup,Bernard Duclos,Carine Foucaud
DOI: https://doi.org/10.1136/gutjnl-2020-322935
IF: 24.5
Gut
Abstract:Objective: Enteropathy-associated T-cell lymphoma (EATL) is a rare but severe complication of coeliac disease (CeD), often preceded by low-grade clonal intraepithelial lymphoproliferation, referred to as type II refractory CeD (RCDII). Knowledge on underlying oncogenic mechanisms remains scarce. Here, we analysed and compared the mutational landscape of RCDII and EATL in order to identify genetic drivers of CeD-associated lymphomagenesis. Design: Pure populations of RCDII-cells derived from intestinal biopsies (n=9) or sorted from blood (n=2) were analysed by whole exome sequencing, comparative genomic hybridisation and RNA sequencing. Biopsies from RCDII (n=50), EATL (n=19), type I refractory CeD (n=7) and uncomplicated CeD (n=18) were analysed by targeted next-generation sequencing. Moreover, functional in vitro studies and drug testing were performed in RCDII-derived cell lines. Results: 80% of RCDII and 90% of EATL displayed somatic gain-of-functions mutations in the JAK1-STAT3 pathway, including a remarkable p.G1097 hotspot mutation in the JAK1 kinase domain in approximately 50% of cases. Other recurrent somatic events were deleterious mutations in nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB) regulators TNFAIP3 and TNIP3 and potentially oncogenic mutations in TET2, KMT2D and DDX3X. JAK1 inhibitors, and the proteasome inhibitor bortezomib could block survival and proliferation of malignant RCDII-cell lines. Conclusion: Mutations activating the JAK1-STAT3 pathway appear to be the main drivers of CeD-associated lymphomagenesis. In concert with mutations in negative regulators of NF-κB, they may favour the clonal emergence of malignant lymphocytes in the cytokine-rich coeliac intestine. The identified mutations are attractive therapeutic targets to treat RCDII and block progression towards EATL.